Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.51 USD | -8.36% | -8.12% | -29.38% |
May. 10 | NetScientific says PDS Biotech's Versamune meets endpoints | AN |
May. 10 | PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 367K | Capitalization | 129M |
---|---|---|---|---|---|
Net income 2024 * | -49M | Net income 2025 * | -61M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 351 x |
P/E ratio 2024 * |
-2.32
x | P/E ratio 2025 * |
-2.21
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on PDS Biotechnology Corporation
1 day | -8.36% | ||
1 week | -8.12% | ||
Current month | +4.78% | ||
1 month | +11.43% | ||
3 months | -34.08% | ||
6 months | -34.27% | ||
Current year | -29.38% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Bedu-Addo
FOU | Founder | 59 | 19-03-14 |
Director of Finance/CFO | 55 | Dec. 03 | |
David Schaaf
CTO | Chief Tech/Sci/R&D Officer | - | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Glover
CHM | Chairman | 60 | 19-04-01 |
Otis Brawley
BRD | Director/Board Member | 64 | 20-11-02 |
Richard Sykes
BRD | Director/Board Member | 79 | 19-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +3.63% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 3.51 | -8.36% | 1,020,015 |
24-05-09 | 3.83 | -4.73% | 1,248,501 |
24-05-08 | 4.02 | +6.49% | 1,844,914 |
24-05-07 | 3.775 | +1.21% | 616,235 |
24-05-06 | 3.73 | -2.36% | 775,623 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.38% | 129M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- PDSB Stock